A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab (Primary) ; Belantamab mafodotin (Primary) ; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms DREAMM-20
Sponsors GlaxoSmithKline

Most Recent Events

11 Feb 2025 Planned End Date changed from 19 Sep 2028 to 3 Dec 2029.
11 Feb 2025 Planned primary completion date changed from 19 Sep 2028 to 3 Dec 2029.
20 Nov 2024 Planned number of patients changed from 124 to 48.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight